# Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

> **NCT02285062** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 570 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** lenalidomide
- **DRUG:** Placebo
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** prednisone
- **DRUG:** vincristine

## Key facts

- **NCT ID:** NCT02285062
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-17
- **Primary completion:** 2019-03-15
- **Final completion:** 2022-07-28
- **Target enrollment:** 570 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02285062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02285062, "Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT02285062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*